Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

H. Lee Moffitt Cancer Center and Research Institute

Status and phase: Enrolling; Phase 2; Phase 1

Conditions: Breast Cancer; Triple Negative Breast Cancer

Treatments: Drug: Zimberelimab; Drug: Sacituzumab govitecan; Radiation: Stereotactic Radiation

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT06238921

MCC-21676

Details and patient eligibility

About

This is a Phase I/II Study to determine the safety and efficacy of Sacituzumab Govitecan and Zimberelimab with stereotactic radiation (SRS) in participants with metastatic triple negative breast cancer with brain metastases, compared to treatment with Sacituzumab Govitecan alone.

Enrollment: 31 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Provision of signed and dated Informed Consent Form (ICF).
• Stated willingness to comply with all study procedures and availability for the duration of the study.
• Age ≥ 18.
• Triple negative breast cancer; to fulfill the requirement of triple negative disease, a breast cancer must express (≤ 5%), by immunohistochemistry (IHC), of the hormone receptors (estrogen receptor [ER] and progesterone receptor [PR]).
• Breast cancer as documented by extracranial tumor biopsy with brain metastases documented from MRI brain imaging or intracranial surgical pathology.
• ≤ 15 brain metastases eligible for Stereotactic radiosurgery (SRS) to brain metastases or to the post-operative bed.
• Measurable brain disease per RANO-BM criteria1 that can be measured in at least one dimension as ≥ 0.5 cm for both intact brain metastases and post-operative cavities.
• Maximum diameter of the largest intact brain metastases ≤ 4 cm.
• Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.
• Symptomatic patients having undergone surgery or on stable doses of steroids ≤ 8 mg/day dexamethasone will be enrolled.
• Prior treatment with taxane based chemotherapy with anthracyclines.
• Individuals with prior SRS/fractioned stereotactic radiotherapy (FSRT) treatment will be allowed if active measurable disease has not previously been treated with radiation therapy.
• Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within 24 hours prior to the administration of each dose of study agent.
• Male and female patients of childbearing potential who engage in heterosexual intercourse must agree to use specified method(s) of contraception.

Exclusion criteria

• Presence of leptomeningeal disease.

• Women who are pregnant or breastfeeding.

• Known history of HIV-1 or 2 with detectable viral load.

• Active, known, or suspected autoimmune disease. Patients with an autoimmune paraneoplastic syndrome requiring concurrent immunosuppressive treatment are excluded. Exceptions are patients with type I diabetes mellitus, hypothyroidism only requiring thyroid replacement therapy, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.

• History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.

• Met any of the following criteria for cardiac disease:

  1. Myocardial infarction or unstable angina pectoris within 6 months of enrollment
  2. History of serious ventricular arrhythmia (ie, ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias requiring antiarrhythmic medications (except for atrial fibrillation that is well controlled with antiarrhythmic medication); history of QT interval prolongation
  3. New York Heart Association (NYHA) Class III or greater congestive heart failure or left ventricular ejection fraction of < 40%

• Any patient requiring supplemental oxygen therapy.

• Have an active serious infection requiring antibiotics.

• Have active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or GI perforation within 6 months of enrollment.

• Patients with prior history of non-breast cancer malignancies are excluded except in the case of adequately treated basal cell cancer, squamous cell skin cancer, chronic lymphocytic leukemia, or other cancers in remission not receiving active therapy for ≥ 2 years.

• Known medical condition that, in the investigator's opinion, would increase the risk associated with study participation or study drug(s) administration or that would interfere with the interpretation of safety results.

• Major surgery or significant traumatic injury that has not been recovered from by 14 days before the initiation of study drug.

• Have had a prior anticancer biologic agent within 4 weeks prior to enrollment or have had prior chemotherapy, targeted small molecule therapy within 2 weeks prior to enrollment and have not recovered.

• Have previously received topoisomerase 1 inhibitors in the setting of brain metastases.

• Use of other investigational drugs (drugs not marketed for any indication) within 28 days or 5 half-lives (whichever is longer) of first dose of study drug.

• Have active Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV). In patients with a history of HBV or HCV, patients with detectable viral loads will be excluded.

• History of allergy or hypersensitivity to any of the study drugs or study drug components.

• Prisoners or individuals who are involuntarily incarcerated.

• Individuals who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Sequential Assignment

Masking: None (Open label)

---

31 participants in 1 patient group

SG + Zimberelimab with SRS

Experimental group

Description:

Treatment will be initiated with SRS followed 1 week later by SG on days 1 and 8 (10mg/kg) with zimberelimab on day 1 (360 mg IV) repeated every 3 weeks follow-up imaging response assessments will be conducted at q9 week intervals.

Treatment:

Radiation: Stereotactic Radiation

Drug: Sacituzumab govitecan

Drug: Zimberelimab